PainReform Ltd. (NASDAQ:PRFX – Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 316,100 shares, an increase of 718.9% from the March 31st total of 38,600 shares. Based on an average trading volume of 2,190,000 shares, the short-interest ratio is presently 0.1 days. Approximately 17.4% of the company’s shares are sold short.
PainReform Price Performance
PainReform stock traded down $0.09 during mid-day trading on Monday, reaching $2.27. 11,762 shares of the company traded hands, compared to its average volume of 1,405,318. The firm’s 50 day moving average price is $2.54 and its 200 day moving average price is $2.90. PainReform has a 52-week low of $1.68 and a 52-week high of $23.27. The firm has a market capitalization of $1.98 million, a price-to-earnings ratio of -0.02 and a beta of 0.72.
Institutional Investors Weigh In On PainReform
An institutional investor recently bought a new position in PainReform stock. Apollon Wealth Management LLC bought a new position in PainReform Ltd. (NASDAQ:PRFX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned approximately 9.23% of PainReform at the end of the most recent quarter. 37.28% of the stock is owned by institutional investors and hedge funds.
PainReform Company Profile
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
Read More
- Five stocks we like better than PainReform
- Consumer Staples Stocks, Explained
- Alphabet Rebounds After Strong Earnings and Buyback Announcement
- How to Profit From Value Investing
- Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Stocks Just Announced Intentions to Buyback Near 10% of Shares
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.
